Clinical Trial Update: Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bortezomib in patients with persistent or recurrent ovarian epithelial cancer or primary peritoneal cancer has completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Epithelial Cancer
• Peritoneal Cancer

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-11-20